We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04196530
Recruitment Status : Active, not recruiting
First Posted : December 12, 2019
Last Update Posted : July 7, 2022
Seven and Eight Biopharmaceuticals Inc
Information provided by (Responsible Party):
Birdie Biopharmaceuticals HK Limited

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 1, 2022
Estimated Study Completion Date : March 1, 2023